MYCN amplification (usually leads to high MYCN expression) occurs in 20–25% of neuroblastomas overall and 40% of high-risk cases18, while elevated MYC expression correlates with poor prognosis in MYCN-nonamplified neuroblastoma19. Here, MYC is linked to neuroblastoma.